1IVF Subspecialist, Infertility Research Center, Mehr Medical Institute, Rasht, Iran
2Master of Developmental Biology, Infertility Research Center, Mehr Medical Institute, Rasht, Iran
3General Practitioner, Infertility Research Center, Mehr Medical Institute, Rasht, Iran
4Gynecologist, Infertility Research Center, Mehr Medical Institute, Rasht, Iran
5Professor of Embriology, Infertility Research Center, Mehr Medical Institute, Rasht, Iran
Background & Aims: Serum progesterone level (as early as 4 weeks gestation) reflects the relation between embryo and corpus luteum. The purpose of the present study was to compare serum progesterone level on day 14 after embryo transfer among 3 groups of patients undergoing intracytoplasmic sperm injection (ICSI) cycles; normal pregnancy (viable intrauterine pregnancy), abnormal pregnancy (miscarriage, ectopic, and biochemical pregnancy), or nonpregnant. Methods: In the present study, 103 patients undergoing ICSI, were retrospectively analyzed. They were divided into 3 groups according to pregnancy outcome; normal pregnancy, abnormal pregnancy, and nonpregnant. Baseline and stimulation characteristics and day 14 progesterone level of patients were compared among groups. Results: Day 14 serum progesterone levels were significantly different among groups; 54.3 ng/ml in normal pregnancy, 39.8 ng/ml in abnormal pregnancy, and 26.2 ng/ml in nonpregnant groups (P < 0.001). No significant differences were observed among the groups in terms of age (P = 0.081), BMI (P = 0.247), baseline follicle-stimulating hormone (FSH) (P = 0.133), and baseline anti-Mullerian hormone (AMH) (P = 0.576), male factor infertility (P = 0.790), total number of retrieved oocyte (P = 0.891), metaphase II oocytes (P = 0.918), and estradiol level on the day of human chorionic gonadotropin (HCG) or human menopausal gonadotropin (HMG) administration (P = 0.838). We determined the 39.5 ng/ml progesterone concentration as the cut-off point with 62% sensitivity and 69% specificity. Conclusion: Despite using the same dose of progesterone supplements, day 14 serum progesterone level was significantly higher in women who achieved normal pregnancy after ICSI compared with others.
Khan-Dawood FS, Goldsmith LT, Weiss G, Dawood MY. Human corpus luteum secretion of relaxin, oxytocin, and progesterone. J Clin Endocrinol Metab 1989; 68(3): 627-31.
Norman RJ, Buck RH, Kemp MA, Joubert SM. Impaired corpus luteum function in ectopic pregnancy cannot be explained by altered human chorionic gonadotropin. J Clin Endocrinol Metab 1988; 66(6): 1166-70.
Fernandez H, Gervaise A. Ectopic pregnancies after infertility treatment: modern diagnosis and therapeutic strategy. Hum Reprod Update 2004; 10(6): 503-13.
Murray H, Baakdah H, Bardell T, Tulandi T. Diagnosis and treatment of ectopic pregnancy. CMAJ 2005; 173(8): 905-12.
Elson J, Salim R, Tailor A, Banerjee S, Zosmer N, Jurkovic D. Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo. Ultrasound Obstet Gynecol 2003; 21(1): 57-61.
Hanita O, Hanisah AH. Potential use of single measurement of serum progesterone in detecting early pregnancy failure. Malays J Pathol 2012; 34(1): 41-6.
Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, et al. Day 14 maternal serum progesterone levels predict pregnancy outcome in IVF/ICSI treatment cycles: a prospective study. Hum Reprod 2005; 20(3): 741-6.
Sonntag B, Loebbecke KC, Nofer JR, Kiesel L, Greb RR. Serum estradiol and progesterone in the mid-luteal phase predict clinical pregnancy outcome in IVF/ICSI cycles. Gynecol Endocrinol 2013; 29(7): 700-3.
Kim JH, Shin MS, Yi G, Jee BC, Lee JR, Suh CS, et al. Serum biomarkers for predicting pregnancy outcome in women undergoing IVF: human chorionic gonadotropin, progesterone, and inhibin A level at 11 days post-ET. Clin Exp Reprod Med 2012; 39(1): 28-32.
Macklon NS, Fauser BC. Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl 2000; 55: 101-8.
Beckers NG, Laven JS, Eijkemans MJ, Fauser BC. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum Reprod 2000; 15(1): 43-9.
Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 2002; 55(1-2): 123-30.
Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002; 17(9): 2287-99.
al-Ramahi M, Perkins S, Claman P. Serum progesterone in predicting pregnancy outcome after assisted reproductive technology. J Assist Reprod Genet 1999; 16(3): 117-20.
Vicdan K, Zeki IA. Luteal phase hormonal profile in prediction of pregnancy outcome after assisted reproduction. Eur J Obstet Gynecol Reprod Biol 2001; 96(1): 98-101.
Katsikis I, Rousso D, Farmakiotis D, Kourtis A, Diamanti-Kandarakis E, Panidis D. Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic and abortive intrauterine gestations. Eur J Obstet Gynecol Reprod Biol 2006; 125(2): 226-32.
Buck RH, Joubert SM, Norman RJ. Serum progesterone in the diagnosis of ectopic pregnancy: a valuable diagnostic test? Fertil Steril 1988; 50(5): 752-5.
Peterson CM, Kreger D, Delgado P, Hung TT. Laboratory and clinical comparison of a rapid versus a classic progesterone radioimmunoassay for use in determining abnormal and ectopic pregnancies. Am J Obstet Gynecol 1992; 166(2): 562-6.
Cabar FR, Fettback PB, Pereira PP, Zugaib M. Serum markers in the diagnosis of tubal pregnancy. Clinics (Sao Paulo) 2008; 63(5): 701-8.